Want to see KMTS full AI Analyst Report?

Kestra Medical Technologies Ltd. (KMTS) Price & Analysis

17 Followers

KMTS Stock Chart & Stats

$19.02

Market closed

$19.02

Day’s Range― - ―

52-Week Range$14.10 - $30.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)310.69K

Market Cap

$1.41B

Enterprise Value$1.06K

Total Cash (Recent Filing)$196.43M

Total Debt (Recent Filing)$4.14M

Price to Earnings (P/E)―

Beta1.06

Next Earnings

Sep 10, 2026

EPS Estimate

-0.63

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.42

Shares Outstanding58,602,497

10 Day Avg. Volume502,173

30 Day Avg. Volume310,694

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)4.66

Price to Sales (P/S)12.72

P/FCF Ratio-10.38

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$30.00

Price Target Upside57.73% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-2.2

Revenue Forecast (FY)$132.89M

Bulls Say, Bears Say

Bulls Say

Revenue Growth & Commercial ScaleKestra has established durable top-line momentum as prescriptions, prescribers and facilities expanded materially. Rapid revenue scaling driven by prescription growth and expanded territories supports market penetration, enabling operating leverage as the commercial footprint matures over multiple quarters.

Gross Margin Expansion & Unit EconomicsMaterial and sustained gross margin improvement indicates improving unit economics and better cost-to-serve for the ASSURE system. A path to 70%+ margins, coupled with detection algorithm updates and RCM/AI improvements, supports long-term profitability potential as utilization and collections improve.

Strengthened Balance Sheet & LiquiditySubstantial cash and a new senior secured term loan provide multi-quarter runway and non-dilutive optionality to fund commercial expansion, RCM investments and potential M&A. This liquidity materially reduces near-term financing risk while the company scales toward positive cash flow.

Bears Say

High Cash Burn & Negative Free Cash FlowKestra continues to consume substantial cash as it invests in commercial scale and RCM capabilities. Persistent negative operating and free cash flow require sustained financing or improved operating leverage; extended cash burn heightens dilution or debt dependence risk if revenue or margin progress slows.

Large Operating LossesDespite revenue growth and gross margin gains, very large operating losses mean the company is not yet creating shareholder returns. Continued negative EBIT pressures long-term ROE and necessitate persistent margin expansion and revenue scale to reach breakeven on an operating basis.

Execution & Conversion Risk From Rapid RampAggressive territory and headcount expansion creates phasing risk: multi-month rep ramp times and variable conversion rates can delay revenue realization and worsen near-term cash burn. Scaling execution across accounts is required to convert underpenetrated demand into durable revenue gains.

Kestra Medical Technologies Ltd. News

Kestra Medical price target raised to $32 from $30 at BTIG

BTIG raised the firm’s price target on Kestra Medical (KMTS) to $32 from $30 and keeps a Buy...

3d ago

KMTS

Kestra Medical sees FY27 revenue $137M, consensus $132.9M

The company said, “Kestra expects revenue of $137 million in FY27, which would represent growth of 44% compared...

3d ago

KMTS

Kestra Medical reports Q4 EPS (67c), consensus (58c)

Reports Q4 revenue $28.64M, consensus $26.48M. “Kestra concluded fiscal year 2026 with another strong quarter of financial performance,...

3d ago

KMTS

Kestra Medical Technologies Earnings Call Highlights Rapid Growth

Kestra Medical Technologies Ltd. (($KMTS)) has held its Q4 earnings call. Read on for the main highlights of...

2d ago

KMTS

Kestra Medical Technologies Reports Strong Fiscal 2026 Growth

Kestra Medical Technologies Ltd. ( ($KMTS) ) has provided an announcement. On July 10, 2026, Kestra Medical Technologies...

3d ago

KMTS

KMTS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Kestra Medical Technologies Ltd. (KMTS) is scheduled to report 4th quarter earnings on 07/14/2026, after the market closes....

6d ago

KMTS

Kestra Medical Technologies’ Earnings Call Highlights Rapid Growth

Kestra Medical Technologies Ltd. (($KMTS)) has held its Q3 earnings call. Read on for the main highlights of...

3M ago

KMTS

KMTS Earnings this Week: How Will it Perform?

Kestra Medical Technologies Ltd. (KMTS) is scheduled to report 3rd quarter earnings on 04/20/2026, after the market closes....

3M ago

KMTS

Kestra Medical price target lowered to $30 from $32 at BTIG

BTIG lowered the firm’s price target on Kestra Medical (KMTS) to $30 from $32 and keeps a Buy...

3M ago

KMTS

Kestra Medical management to meet with Piper Sandler

Meetings to be held in Europe April 8-9 hosted by Piper Sandler. Published first on TheFly – the...

4M ago

KMTS

Kestra Medical files automatic common shares offering

16:35 EDT Kestra Medical (KMTS) files automatic common shares offering Published first on TheFly – the ultimate source...

4M ago

KMTS

Kestra Medical management to meet virtually with BTIG

Virtual Meeting to be held on April 1-2 hosted by BTIG. Published first on TheFly – the ultimate...

4M ago

KMTS

Kestra Medical reports Q3 EPS (61c), consensus (60c)

Reports Q3 revenue $24.55M, consensus $22.87M. “Kestra delivered another strong quarter of financial performance, generating revenue growth of...

4M ago

KMTS

Kestra Medical raises FY26 revenue view to $93M from $91M, consensus $90.94M

The company said, “Kestra is increasing its FY26 revenue guidance to $93 million, which would represent growth of...

4M ago

KMTS

KMTS FAQ

What was Kestra Medical Technologies Ltd.’s price range in the past 12 months?

Kestra Medical Technologies Ltd. lowest stock price was $14.10 and its highest was $30.00 in the past 12 months.

What is Kestra Medical Technologies Ltd.’s market cap?

Kestra Medical Technologies Ltd.’s market cap is $1.41B.

When is Kestra Medical Technologies Ltd.’s upcoming earnings report date?

Kestra Medical Technologies Ltd.’s upcoming earnings report date is Sep 10, 2026 which is in 55 days.

How were Kestra Medical Technologies Ltd.’s earnings last quarter?

Kestra Medical Technologies Ltd. released its earnings results on Jul 14, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.08.

Is Kestra Medical Technologies Ltd. overvalued?

According to Wall Street analysts Kestra Medical Technologies Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kestra Medical Technologies Ltd. pay dividends?

Kestra Medical Technologies Ltd. does not currently pay dividends.

What is Kestra Medical Technologies Ltd.’s EPS estimate?

Kestra Medical Technologies Ltd.’s EPS estimate is -0.63.

How many shares outstanding does Kestra Medical Technologies Ltd. have?

Kestra Medical Technologies Ltd. has 58,602,497 shares outstanding.

What happened to Kestra Medical Technologies Ltd.’s price movement after its last earnings report?

Kestra Medical Technologies Ltd. reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went up 1.799%.

Which hedge fund is a major shareholder of Kestra Medical Technologies Ltd.?

Currently, no hedge funds are holding shares in KMTS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kestra Medical Technologies Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-68.83%

Trailing 12-Months

Asset Growth

21.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kestra Medical Technologies Ltd.

Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.

Kestra Medical Technologies Ltd. (KMTS) Earnings & Revenues

Historic Earnings Reports

KMTS Stock 12 Month Forecast

Average Price Target

$30.00

▲(57.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","33":"$33","18.75":"$18.75","23.5":"$23.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18.75,23.5,28.25,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.28,26.720000000000002,27.16,27.6,28.04,28.48,28.92,29.36,29.8,30.240000000000002,30.68,31.12,31.56,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.28,26.566153846153846,26.852307692307694,27.138461538461538,27.424615384615386,27.71076923076923,27.99692307692308,28.283076923076923,28.56923076923077,28.855384615384615,29.141538461538463,29.427692307692308,29.713846153846156,{"y":30,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.28,26.412307692307692,26.544615384615387,26.676923076923078,26.80923076923077,26.941538461538464,27.073846153846155,27.206153846153846,27.338461538461537,27.470769230769232,27.603076923076923,27.735384615384614,27.86769230769231,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.82,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >